Visit Nail'n'Toe on Facebook
Nail'n'Toe online anti fungal store
foot care for toenail fungus
Care kits for fungus treatment

Archive for the ‘References’ Category

Onychomycosis Research References

  1. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol
    1992; 126 (Suppl. 39): 23–7.
  2. Sais G, Jucgla J, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758–61.
  3. Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699–703.
  4. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in north eastern Ohio for other conditions. Arch Dermatol 1997; 133: 1172–3.
  5. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non dermatophyte filamentous fungi. Mycoses 1989; 32: 609–19.
  6. Evans EGV, Gentles JC. Essentials of Medical Mycology. Edinburgh: Churchill Livingstone, 1985.
  7. Detandt M, Nolard M. Fungal contamination of the floors of swimming pools, particularly subtropical swimming paradises. Mycoses 1995; 38: 509–13.
  8. Drake LA, Sher RK, Smith EB et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702–4.
  9. English MP, Atkinson E. Nail mycology in chiropody patients. Br J Dermatol 1974; 91: 67–72.
  10. Zaug M, Bergstraesser M. Amorolfine in onychomycosis and dermatomycosis. Clin Exp Dermatol 1992; 17 (Suppl. 1): 61–70.
  11. Hay RJ, MacKie RM, Clayton YM. Tioconazole nail solution – an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111–15.
  12. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost effective treatment for onychomycosis. Br J Dermatol 2001; 145 (Suppl. 60): 15–19.
  13. Roobol A, Gull K, Pogson CI. Griseofulvin-induced aggregation of microtubule protein. Biochem J 1977; 167: 39–43.
  14. Wehland DJ, Herzoy W, Weber K. Interaction of griseofulvin with microtubules, microtubular proteins and tubulin. J Mol Biol 1977; 111: 329–42.
  15. Roobol A, Gull K, Pogson CI. Evidence that griseofulvin binds to a microtubular protein. FEBS Lett 1977; 29: 149–53.
  16. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. Br Med J 1967; iii: 464–8.
  17. Faergemann J, Andreson C, Hersle K et al. Double-blind, parallel group comparison of terbinafine and griseofulvin in treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750–3.
  18. Haneke E, Tausch I, Brautigam M et al. Short duration treatment of fingernail dermatophytosis: a randomised double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72–7.
  19. Hofmann H, Brautigam M, Weidinger G et al. Treatment of toenail onychomycosis. A randomised, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919–22.
  20. Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis. Open and double-blind studies. Acta Derm Venereol (Stockh) 1990; 70: 137–40.
  21. Korting HC, Schafer-Korting M, Zienicke H et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37: 2064–8.
  22. Cribier BJ, Paul C. Long-term efficacy of antifungals in toenail onychomycosis: a critical review. Br J Dermatol 2001; 145: 446–52.
  23. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmcother 1997; 8: 275–88.
  24. Ryder NS, Leitner I. In vitro activity of terbinafine; an update. J Dermatol Treat 1998; 9 (Suppl. 1): S23–8.
  25. Clayton YM. Relevance of broad spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 (Suppl. 43): 7–8.
  26. Faergemann J. Pharmacokinetics of terbinafine. Rev Contemp Pharmacother 1997; 8: 289–97.
  27. Brautigam M, Nolting S, Schopf RE et al. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Br Med J 1995; 311: 919–22.
  28. de Backer M, de Keyser P, de Vroey C et al. 12 week treatment for dermatophyte toenail onychomycosis: terbinafine 250 mg vs itraconazole 200 mg per day: a double-blind comparative trial. Br J Dermatol 1996; 134 (Suppl. 46): 16–17.
  29. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomised comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34: 138–43.
  30. Tosti A, Piraccini BM, Stinchi C et al. Treatment of dermatophyte nail infections: an open randomised study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent intraconazole therapy. J Am Acad Dermatol 1996; 34: 595–600.
  31. Evans EGV, Sigurgeirsson B, Billstein S. European multicentre study of continous terbinafine vs intermittent itraconazole in the treatment of toenail onychomycosis. Br Med J 1999; 318: 1031–5.
  32. Sigurgeirsson B, Olaffson JH, Steinssen JB et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353–7.
  33. Crawford F, Young P, Godfrey C et al. Oral treatments for toenail onychomycosis. A systematic review. Arch Dermatol 2002; 138: 811–16.
  34. Gupta AK, Shear NJ. The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venereol 1999; 13: 1–3.
  35. Gupta AK, Gregurek-Novak T. Efficacy of itraconzole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001; 202: 235–8.
  36. Gupta AK, Daniel CR. Factors that may affect the response of onychomycosis to oral antifungal therapy. Australas J Dermatol 1998; 39: 222–4.
  37. Roberts DT, Evans EGV. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998; 138: 189–90.
  38. Griffiths CEM. The British Association of Dermatologists guidelines for the management of skin disease. Br J Dermatol 1999; 141: 396–7.
  39. Cox NH, Williams HC. The British Association of Dermatologists therapeutic guidelines: can we AGREE? Br J Dermatol, in press.